

Ann Arbor, Michigan, USA | June 23, 2022

Ground-breaking Ceremony for Center of Excellence in Ann Arbor

- 130,000-square-foot plant in Ann Arbor, Michigan
- Number of jobs is expected to more than double within three years
- Opening of facility by year end 2023

Sartorius, a leading international partner of the life science research and the biopharmaceutical industry, announced today it is breaking ground on its new 130,000-square foot (12,000 square meter) Center of Excellence for BioAnalytics at 3874 Research Park Drive in the Tech Loop at the Ann Arbor Research Park in Ann Arbor, Michigan.

The company has purchased 16 acres of land which provides sufficient space for further expansion. Currently, there are about 140 employees in the Ann Arbor area, and this project is expected to increase that number to about 300 within three years. These jobs will include product development, operations, and other support functions.

The state-of-the-art facility, set to open by year end 2023, will consolidate existing business operations from Washtenaw County and other sites to create a Center of Excellence for BioAnalytics in North America, which focuses on providing advanced solutions to help customers develop drugs that cure, prevent, and halt the progression of diseases.

"Sartorius is continuously growing and innovating, and this new facility in Ann Arbor will help the company meet the increasing demand for our products and services worldwide. The plant will house all our existing sites and functions already based in Ann Arbor for BioAnalytics, Microcarriers, and Particle Validation Standards. In addition, we will build a Process Development Laboratory to support the Advanced Therapies market. Moreover, driving efficiencies in our businesses processes will support our growth plans," said Mary Lavin, President of Sartorius North America.

The site, which is seeking LEED certification for new construction and major renovation by the U.S. Green Building Council, offers sustainable features including capacity for up to 75 electric vehicle charging stations, 200 kilowatt solar panels on the roof, and the research park's first storm runoff pond to protect against flooding and erosion.

This extension is part of Sartorius' ongoing worldwide expansion to support the development and production of biopharmaceuticals, enabling Sartorius to scale up its operations and capabilities in the Ann Arbor biotech hub.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2021, the company earned sales revenue of some 3.45 billion euros. At the end of 2021, nearly 14,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Timo Lindemann

Press Relations

+49 (0)551.308.4724

timo.lindemann@sartorius.com

Follow Sartorius on [Twitter](#) @Sartorius_Group and on [LinkedIn](#).